HRP20040195B1 - Cjepivo protiv bolesti zapadnoga nila - Google Patents

Cjepivo protiv bolesti zapadnoga nila

Info

Publication number
HRP20040195B1
HRP20040195B1 HRP20040195AA HRP20040195A HRP20040195B1 HR P20040195 B1 HRP20040195 B1 HR P20040195B1 HR P20040195A A HRP20040195A A HR P20040195AA HR P20040195 A HRP20040195 A HR P20040195A HR P20040195 B1 HRP20040195 B1 HR P20040195B1
Authority
HR
Croatia
Prior art keywords
west nile
vaccine
provides
vaccine composition
disease
Prior art date
Application number
HRP20040195AA
Other languages
English (en)
Croatian (hr)
Inventor
Hsien-Jue Chu
Original Assignee
Zoetis W Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis W Llc filed Critical Zoetis W Llc
Publication of HRP20040195A2 publication Critical patent/HRP20040195A2/hr
Publication of HRP20040195B1 publication Critical patent/HRP20040195B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20040195AA 2001-07-27 2002-07-23 Cjepivo protiv bolesti zapadnoga nila HRP20040195B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (2)

Publication Number Publication Date
HRP20040195A2 HRP20040195A2 (en) 2004-08-31
HRP20040195B1 true HRP20040195B1 (hr) 2014-07-18

Family

ID=27613166

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040195AA HRP20040195B1 (hr) 2001-07-27 2002-07-23 Cjepivo protiv bolesti zapadnoga nila

Country Status (24)

Country Link
US (8) US7153513B2 (enExample)
EP (3) EP1427444B1 (enExample)
JP (2) JP4718778B2 (enExample)
KR (2) KR20040028952A (enExample)
CN (2) CN1935258B (enExample)
AU (1) AU2002365244B2 (enExample)
BE (1) BE2014C006I2 (enExample)
BR (1) BRPI0211492B1 (enExample)
CA (1) CA2452545C (enExample)
CY (1) CY2014010I2 (enExample)
DK (1) DK1427444T3 (enExample)
ES (1) ES2435095T3 (enExample)
FR (1) FR14C0016I2 (enExample)
HR (1) HRP20040195B1 (enExample)
HU (2) HU228690B1 (enExample)
LU (1) LU92348I2 (enExample)
ME (1) ME00491B (enExample)
MX (1) MXPA04000680A (enExample)
NZ (3) NZ570270A (enExample)
PL (2) PL220846B1 (enExample)
PT (1) PT1427444E (enExample)
RS (1) RS53184B (enExample)
WO (1) WO2003061555A2 (enExample)
ZA (1) ZA200401596B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
ES2435095T3 (es) * 2001-07-27 2013-12-18 Zoetis W Llc Vacuna del Nilo Occidental
US7585621B2 (en) * 2003-09-09 2009-09-08 Idexx Laboratories, Inc. Detection of West Nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EP1863528A2 (en) * 2005-04-01 2007-12-12 Wyeth Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
EP1896069B1 (en) * 2005-06-24 2013-03-13 Intervet International BV Inactivated chimeric vaccines and related methods of use
EP2407480B1 (en) * 2005-10-19 2014-07-16 University of Florida Research Foundation, Incorporated Materials for respiratory disease control in canines
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
CA2646623A1 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma Rna virus vaccines and methods
DK2027155T3 (en) * 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
US9056909B2 (en) * 2007-11-06 2015-06-16 Zoetis Services Llc Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
US9642908B2 (en) * 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
SG193821A1 (en) * 2008-08-29 2013-10-30 Boehringer Ingelheim Vetmed West nile virus vaccine
MX2012004133A (es) * 2009-10-07 2012-05-08 Wyeth Llc Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas.
AU2012229192B2 (en) 2011-03-14 2017-04-20 Boehringer Ingelheim Animal Health USA Inc. Equine Rhinitis vaccine
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
SI3542819T1 (sl) * 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
MX2016002903A (es) * 2013-09-05 2016-06-06 Zoetis Services Llc Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
US12350328B2 (en) 2019-02-27 2025-07-08 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (EIV) in horses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020071A1 (fr) * 1993-03-08 1994-09-15 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile metabolisable
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
WO2002072036A2 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
WO2002081754A1 (en) * 2001-04-04 2002-10-17 The Governement Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2002081621A2 (fr) * 2001-04-06 2002-10-17 Merial Vaccin contre le virus de la fievre du nil

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
WO1999063095A1 (en) 1998-06-04 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
AU2002211490A1 (en) * 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20050048073A1 (en) 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
ES2435095T3 (es) * 2001-07-27 2013-12-18 Zoetis W Llc Vacuna del Nilo Occidental
US7785799B2 (en) 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020071A1 (fr) * 1993-03-08 1994-09-15 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile metabolisable
US6235282B1 (en) * 1993-03-08 2001-05-22 Rhone Merieux Vaccinal fluid water-in-oil emulsions containing a metabolizable oil
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
WO2002072036A2 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
WO2002081754A1 (en) * 2001-04-04 2002-10-17 The Governement Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2002081621A2 (fr) * 2001-04-06 2002-10-17 Merial Vaccin contre le virus de la fievre du nil

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALLISON A C: "SQUALENE AND SQUALANE EMULSIONS AS ADJUVANTS" METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 19, 1999, pages 87-93, XP001015570 ISSN: 1046-2023 *
ANDERSON J.F. ET AL.: 'Isolation of West Nile virus from Mosquitoes, Crows and a Cooper's Hawk in Connecticut' SCIENCE vol. 286, December 1999, pages 2331 - 2333, XP002191030 *
ARROYO J ET AL: "Yellow fever vector live-virus vaccines: West Nile virus vaccine development" TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, vol. 7, no. 8, August 2001 (2001-08), pages 350-354, XP002367847 ISSN: 1471-4914 *
DAVIS B S ET AL: "West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 9, May 2001 (2001-05), pages 4040-4047, XP002239873 ISSN: 0022-538X *
LUSTIG S ET AL: "A LIVE ATTENUATED WEST NILE VIRUS STRAIN AS A POTENTIAL VETERINARY VACCINE" VIRAL IMMUNOLOGY, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 13, no. 4, December 2000 (2000-12), pages 401-410, XP008018324 ISSN: 0882-8245 *
MONATH T P ET AL: "West Nile virus vaccine" CURRENT DRUG TARGETS, BENTHAM SCIENCE PUBLISHER,, US, vol. 1, no. 1, May 2001 (2001-05), pages 37-50, XP002967300 ISSN: 1389-4501 *
SENNE D.A. ET AL.: 'Pathogenicity of West Nile virus in Chickens' AVIAN DISEASES vol. 44, 2000, pages 642 - 649, XP002969115 *

Also Published As

Publication number Publication date
WO2003061555A3 (en) 2004-04-15
US20070231350A1 (en) 2007-10-04
NZ570270A (en) 2010-08-27
US20030091595A1 (en) 2003-05-15
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
CN1535157A (zh) 2004-10-06
US7648706B2 (en) 2010-01-19
CY2014010I1 (el) 2020-05-29
PL398575A1 (pl) 2012-06-18
DK1427444T3 (da) 2013-11-04
BRPI0211492B1 (pt) 2016-06-21
ME00491B (me) 2011-10-10
LU92348I2 (fr) 2014-09-22
BR0211492A (pt) 2004-08-17
EP2283858A2 (en) 2011-02-16
US7153513B2 (en) 2006-12-26
PL368535A1 (en) 2005-04-04
PL212212B1 (pl) 2012-08-31
NZ531265A (en) 2008-08-29
EP1427444A4 (en) 2008-01-02
US20070166326A1 (en) 2007-07-19
CN1935258A (zh) 2007-03-28
WO2003061555A2 (en) 2003-07-31
HUP0401606A2 (hu) 2004-11-29
NZ553165A (en) 2008-09-26
JP2011057692A (ja) 2011-03-24
KR20040028952A (ko) 2004-04-03
AU2002365244B2 (en) 2007-12-06
RS53184B (sr) 2014-06-30
CA2452545C (en) 2015-06-09
MXPA04000680A (es) 2004-04-05
LU92348I9 (enExample) 2019-01-02
US20070231349A1 (en) 2007-10-04
KR20090053967A (ko) 2009-05-28
PT1427444E (pt) 2013-11-19
HUS1300055I1 (hu) 2016-08-29
ES2435095T3 (es) 2013-12-18
US20070166802A1 (en) 2007-07-19
US7445787B2 (en) 2008-11-04
CN1273189C (zh) 2006-09-06
JP2005515236A (ja) 2005-05-26
US20070166324A1 (en) 2007-07-19
FR14C0016I2 (fr) 2015-07-24
EP2283858A3 (en) 2011-03-23
YU8004A (sh) 2006-08-17
US7648705B2 (en) 2010-01-19
CA2452545A1 (en) 2003-07-31
PL220846B1 (pl) 2016-01-29
HK1066470A1 (en) 2005-03-24
HUP0401606A3 (en) 2005-02-28
BE2014C006I2 (enExample) 2021-02-04
US20070178119A1 (en) 2007-08-02
HU228690B1 (en) 2013-05-28
EP2281572A1 (en) 2011-02-09
ZA200401596B (en) 2005-07-27
US20070166325A1 (en) 2007-07-19
CY2014010I2 (el) 2024-02-16
FR14C0016I1 (enExample) 2014-03-28
CN1935258B (zh) 2013-04-03
HRP20040195A2 (en) 2004-08-31
JP4718778B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
MXPA04000680A (es) Vacuna para virus west nile.
PY0111577A (es) Métodos y composiciones para el tratamiento del virus de la hepatitis c
UY27466A1 (es) Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
EA200300023A1 (ru) 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ
BR0114393A (pt) Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado
ATE499113T1 (de) Influenzavirus-impfstoffzusammensetzung
CO5050303A1 (es) Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion
PE20070221A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
UY27333A1 (es) Nucleótidos 4` sustituidos
ATE350057T1 (de) Impfstoffzusammesetzung
BRPI9701774B8 (pt) cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
MY153290A (en) Multivalent avian influenza vaccines
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
DE60120840D1 (de) Impfstoffe basierend auf Mutanten des Virus der infektiösen Bursal-Krankheit
CY1114624T1 (el) Εμβολιο δυτικου νειλου
DK1237571T3 (da) Toscana-virus-nukleinprotein
AR035166A1 (es) Composiciones mejoradoras inmunomoduladoras y neutralizantes de anticuerpos. vacuna y metodo de tratamiento
RU2005139920A (ru) Способ специфической профилактики вирусного гепатита b у взрослых, больных острыми лейкозами

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: WYETH LLC, US

Owner name: ZOETIS W LLC, US

PPPP Transfer of rights

Owner name: PAH W LLC, US

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: ZOETIS SERVICES LLC, US

PNAN Change of the applicant name, address/residence

Owner name: ZOETIS SERVICES LLC, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190711

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200722

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210713

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20220723